Eletriptan - Medication and Pregnancy KB

Eletriptan

Exposed non-exposed studies (cohort)

Study	Country Study period	Population source	Exposure definition	Non-exposure definition	Sample size	Rmk
Källén (control exposed to ergots), 2011	Sweden 1995 - 2008	All deliveries in Sweden (1 211 670 women) recorded in the Medical Birth Register with data from antenatal care.	Infants born to women who had used Eletriptan during pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).	exposed to other treatment, sick Infants born to women who had used Ergots drugs for migraine during pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).	14 / 527	Exposed groups of the whole study: drugs for migraine (ergots or triptans).
Källén (control unexposed, disease free), 2011	Sweden 1995 - 2008	All deliveries in Sweden (1 211 670 women) recorded in the Medical Birth Register with data from antenatal care.	Infants born to women who had used Eletriptan during pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed, disease free Infants born to women who did not use drugs for migraine.	14 / 1229901	Exposed groups of the whole study: drugs for migraine (ergots or triptans). 1229901= Total number of infants (n=1233228) - Number of infants whose mother used drugs for migraine in 1st trimester (n=3327)
Nezvalová-Henriksen (Control unexposed, disease free), 2013	Norway 2004 - 2007	All singleton deliveries (after the 12th gestational week) without chromosomal abnormalities during the study period.	Eletriptan prescription redemption during pregnancy ('anytime' or 'during the first trimester' or 'during the second trimester' or 'during the third trimester'). (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed, disease free Pregnant women did not redeem triptans during the study period (the population comparison group).	207 / 178565
Nezvalová-Henriksen (Control unexposed, sick), 2013	Norway 2004 - 2007	All singleton deliveries (after the 12th gestational week) without chromosomal abnormalities during the study period.	Eletriptan prescription redemption during pregnancy ('anytime' or 'during the first trimester' or 'during the second trimester' or 'during the third trimester'). (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed, sick Triptan prescription redemption between 7 and 1 month prior to pregnancy only.	207 / 1095
Spielmann (Control mainly exposed other treatments, sick), 2017	Germany 1999 - 2014	Cohort of pregnant women enrolled by the German Embryotox system for risk assessment related to pregnancy.	Pregnant women with Eletriptan use for migraine disorder any time from conception to delivery. (This is a subgroup of exposure among the whole exposed group considered in the study).	exposed to other treatment, sick Pregnant women suffering from migraine disorder but not taking triptans between their last menstrual period and delivery.	18 / 475	The majority of exposed women took triptans in the first trimester (75.2%). Sumatriptan was the most frequently used triptan. Other triptans also studied.
Spielmann (Control unexposed, disease free), 2017	Germany 1999 - 2014	Cohort of pregnant women enrolled by the German Embryotox system for risk assessment related to pregnancy.	Pregnant women with Eletriptan use for migraine disorder any time from conception to delivery. (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed, disease free Pregnant women without migraine disorder who were neither exposed to triptans nor to one of the following established teratogens or fetotoxicant.	18 / 1733	The majority of exposed women took triptans in the first trimester (75.2%). Sumatriptan was the most frequently used triptan. Other triptans also studied.

Case-control studies (cohort)

Study	Country Study period	Case	Control	Sample size	Rmk

Warning! There are no case-control studies available for this drug.

master protocol